Business Wire

RSA Announces CEO Transition to Lead New Phase of Growth

5.9.2025 13:00:00 CEST | Business Wire | Press Release

Share

RSA, the security-first identity leader, backed by Clearlake Capital Group, L.P. (together with its affiliates) and STG, today announced that Greg Nelson, current President and Chief Business Officer, will succeed Rohit Ghai as Chief Executive Officer on September 15, 2025. Mr. Ghai will transition to a strategic advisory role after serving almost eight years as CEO.

Mr. Nelson, a seasoned SaaS executive who has more than 30 years of software, data, technology and private equity experience, is expected to lead RSA into this next phase of accelerated growth. The company’s strategic growth initiatives and investments will focus on:

  1. Passwordless – Eliminating reliance on passwords to improve security and user experience
  2. Artificial Intelligence (AI) – Leveraging AI to enhance threat detection, prevention, and response
  3. Posture Management – Strengthening governance, risk, and compliance capabilities
  4. Highest-assurance identity solutions – Protecting the most security-sensitive organizations

“With favorable market trends and clear competitive advantages, we believe RSA is uniquely positioned to accelerate its growth,” said Prashant Mehrotra, Partner and Managing Director at Clearlake Capital Group. “We are confident that Greg’s leadership and focus on innovation across these four strategic pillars will drive the company’s momentum in the years ahead.”

Mr. Nelson has been with RSA for nearly four years, reimagining the company’s go-to-market approach to be customer-first and growth-focused. In his role as CEO, Mr. Nelson will continue working to build RSA’s strong foundation to deliver innovation and scale in ways that meet the evolving needs of its global customer base.

“RSA has built momentum, and we’re ready to move faster, innovate more boldly, and scale our business to capture new opportunities,” said Mr. Nelson, incoming CEO of RSA. “We have a clear strategy, a strong market position, and the investment we need to execute. This is an incredibly exciting time for RSA, our customers, and our employees.”

Under Mr. Ghai’s leadership, RSA navigated its carve-out from Dell Technologies, separated into independent businesses, returned to growth, and modernized its core offerings. During this time the company also sharpened its focus on identity security, transformed from an on-premises point product company to a SaaS-based identity security platform, and reaffirmed its leadership in serving the world’s most security-sensitive organizations.

“Rohit has led RSA through a period of remarkable transformation,” said Ed Didier, Managing Director at STG. “He strengthened the company’s market position, built a high-performing team, and set the stage for accelerated growth under new leadership. On behalf of the Board, we would like to thank Rohit for his contribution, and we’re pleased he will continue to serve as an advisor to the company going forward.”

About RSA

RSA provides mission-critical cybersecurity solutions that protect the world’s most security-sensitive organizations. The RSA Unified Identity Platform provides true passwordless identity security, risk-based access, automated identity intelligence, and comprehensive identity governance across cloud, hybrid, and on-premises environments. More than 9,000 high-security organizations trust RSA to manage more than 60 million identities, detect threats, secure access, and enable compliance. For additional information, visit our website to contact sales, find a partner, or learn more about RSA.

About Clearlake Capital Group, L.P.

Clearlake Capital Group is a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies. Founded in 2006, the firm has more than $90 billion of assets under management and has led or co-led over 400 investments globally. With deep knowledge and operational expertise across the technology, industrials, and consumer sectors, Clearlake seeks to partner with experienced management teams, providing patient, long-term capital and aiming to drive value through its active hands-on operating approach, O.P.S.® (Operations, People, Strategy). Headquartered in Santa Monica, Clearlake maintains a global footprint with offices in Dallas, London, Dublin, Luxembourg, Abu Dhabi, and Singapore. For more information, please visit clearlake.com or follow us on LinkedIn.

About STG

STG is a private equity partner to market leading companies in data, software, and analytics. The firm brings experience, flexibility, and resources to build strategic value and unlock the potential of innovative companies. Partnering with a goal to build customer-centric, market winning portfolio companies, STG seeks to create sustainable foundations for growth that bring value to existing and future stakeholders. The firm is dedicated to transforming and building outstanding technology companies in partnership with world class management teams. STG’s expansive portfolio has consisted of more than 50 global companies. For more information, please visit http://www.stg.com/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250905958809/en/

Contacts

Media Contact:
teamrsa@axicom.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye